• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Fusion Pharmaceuticals Acquires IPN-1087

    Strata Oncology Unveils Strata PATH Trial
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery

    Injectable Drug Delivery Trends

    Oral Solids: Market & Technology Trends
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    Emergent BioSolutions

    Alcami

    Syngene

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Adare Pharma Solutions

    Reed-Lane

    Aphena Pharma Solutions

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Early Development Trends

    Catalent’s president of oral drug delivery, Jonathan Arnold, talks trends and challenges in the early phases of drug development.

    Early Development Trends
    Related CONTENT
    • Legacy Pharma Solutions
    • PCI Pharma Services
    • Catalent Pharma Solutions
    • Regis Custom Pharma
    • Softweb Solutions
    Tim Wright, Editor, Contract Pharma03.06.19
    As one of the leading contract development and manufacturing organizations (CDMO) providing drug delivery technologies and development solutions, Catalent offers worldwide clinical and commercial supply capabilities for drugs, biologics, and consumer health products. With over 11,000 employees, including more than 1,800 scientists, Catalent works with over 1,000 customers to produce 73 billion doses of nearly 7,000 products annually. This equates to approximately 1 in 20 doses taken each year by patients or consumers around the globe.

    In the last two years Catalent has made two major acquisitions. First, in 2017 the CDMO purchased Cook Pharmica’s facility in Bloomington, IN, expanding its biologics development capabilities. In 2018, the company acquired the UK-based Juniper Pharmaceuticals, an early-phase development and manufacturing company.

    Contract Pharma had the chance to sit down with Catalent’s president of oral drug delivery, Jonathan Arnold, to talk about the challenges and opportunities the company faces and its growth in early development and new technologies.

    Contract Pharma (CP): Describe the Juniper deal and how it expands Catalent’s early phase capabilities.

    Jonathan Arnold (JA):
    In August 2018, we acquired Juniper Pharmaceuticals, Inc., including its Nottingham, UK-based Juniper Pharma Services division. The $133 million acquisition expands and further strengthens Catalent’s offerings in formulation development, bioavailability enhancement solutions and solid oral dose manufacturing, and complements our integrated downstream global clinical and commercial supply network.

    The Nottingham facility now acts as a European center of excellence for early phase development and its nearly 150 employees, who have deep scientific expertise in formulation development and supply, are now fully integrated within the Catalent organization.

    The Nottingham facility specializes in solid-state characterization and preclinical formulation screening for lead-candidate selection, phase-appropriate dose-form development, and formulation technologies to address challenging molecules, which further strengthen and expand on our capabilities to accelerate clinical development and offers our customers’ opportunities to begin optimizing formulations earlier and potentially reducing the risk of failure later in development.

    CP: What are some other business highlights over the past 12 months?

    JA:
    Earlier in 2018, before we acquired Juniper, we also announced that we were investing $5 million in the creation of a focused drug development center of excellence at our Somerset, NJ facility and headquarters. The site will focus on preclinical to clinical phase 2b formulation, analytical, and manufacturing solutions for orally delivered small molecules, as well as specializing in the development of modified and controlled release formulations. The investment will build upon the site’s expertise in clinical dose form strategies, and its handling capabilities for potent compounds, and will provide many of the same capabilities as its sister sites in Nottingham UK and on the west coast of the U.S., in San Diego.

    Alongside the new centers of excellence, we are implementing systems that ensure the seamless tech transfer of programs downstream into our late-stage clinical and commercial manufacturing sites. This includes a process of harmonizing raw materials; specifications; analytical methods; environmental, health and safety considerations; and mirrored manufacturing equipment for improved scalability and project management systems. The goal is to provide greater speed, cost efficiency and reduced risk to projects as they progress through the clinic to commercialization. Our San Diego site has successfully transferred multiple development programs to our Kansas City, MO site for late stage scale-up, which led to cost and time savings compared to external transfer to a different provider.

    CP: What are some of the most pressing challenges facing the industry and CDMOs in particular?

    JA:
    At Catalent we continue to see a growing need for solutions that improve the bioavailability of poorly soluble new chemical entities. We have built up a wide-ranging portfolio of capabilities to enhance oral bioavailability, including development of amorphous dispersions with spray drying and hot melt extrusion, particle-size reductions with micronization and nano-milling, and lipid-based delivery systems.

    We aim to match the best technology for clinical success using an agnostic, data-driven process, where the formulation and dose strategy is driven by the attributes of the particular molecule, the manufacturing process intended, key patient acceptance factors, and our customers’ strategic product goals.

    Today’s drug development pipeline is increasingly complex, and molecules with delivery challenges are commonplace. With many programs now driven by small, venture-capital backed companies without the resources of large pharma, finished dose outsourcing will increase. The number of new drugs approved per billion U.S. dollars spent is falling, mainly because of a lack of efficacy, often discovered at phase 2 or later, when significant resource has already been invested. The industry needs to focus on those programs that offer the best chance of the molecule reaching, engaging with the target, and eliciting a desired response, and killing other programs before spending more on them. It’s far too expensive to develop all candidates that show promise, and that is why customers often turn to development partners to help get to a scientifically based “go/no go” decision quickly.

    There is increasing recognition that for a patient to comply with their dosing regimen, we need to make drugs in forms that aid their compliance all the way to the end of the course of treatment. While it was once sufficient to be able to treat a condition, there is an increasing focus on how patients can continue to live a normal life with their condition. Many patients endure having to take multiple medicines at whatever prescribed interval throughout the day, that may be hard to swallow, taste awful, or induce some undesirable side effect, but apply those same conditions to the young, the old, or the already infirm and most would agree we need to find better treatment technologies.

    CP: What are some of Catalent’s most recent technological breakthroughs?

    JA:
    We have recently developed the Zydis Ultra oral disintegrating tablet (ODT), which builds on the Zydis fast dissolve tablet technology. Zydis Ultra technology involves a novel API coating technology to increase drug load per unit dose. The advantages of ODTs over conventional oral dosage forms are well established and documented and are principally related to improved patient compliance, adherence and convenience. These are particularly evident within such groups as pediatrics, geriatrics and mental health patients who more frequently have problems swallowing tablets.

    However, a significant challenge with ODT dosage forms is the formulation of APIs with an extremely bitter taste or a propensity to cause stinging, burning or numbing within the mouth. Usually, ODT drug loading is limited to 100 mg per dose, however, Zydis Ultra technology overcomes this through the use of a patented API coating technology that draws on both acoustic mixing/coating and lyophilization. It will therefore significantly broaden the number of molecules that can potentially be formulated using Zydis ODT technology, and this next generation of ODTs will have broad industry potential to improve patient compliance, adherence and convenience, as well as expanding the applicability of the ODT platform to a greater range of compounds.

    To date, industry response has been overwhelmingly positive, and we have now entered proof-of-concept programs and full development with several customers, for both over-the-counter and prescription therapies. 
    Related Searches
    • late-stage
    • equipment
    • tablets
    • Dosage
    Suggested For You
    Legacy Pharma Solutions Legacy Pharma Solutions
    PCI Pharma Services PCI Pharma Services
    Catalent Pharma Solutions Catalent Pharma Solutions
    Regis Custom Pharma Regis Custom Pharma
    Softweb Solutions Softweb Solutions
    Vetio Animal Health Vetio Animal Health
    Adare Pharma Solutions Adare Pharma Solutions
    Contracting And Outsourcing Exhibitor List Contracting And Outsourcing Exhibitor List
    Catalent Appoints Tech Ops SVP Catalent Appoints Tech Ops SVP
    Catalent Enters Clinical Supply Partnership with Adial Catalent Enters Clinical Supply Partnership with Adial
    Catalent Receives P&G Award Catalent Receives P&G Award
    Catalent Appoints President & COO Catalent Appoints President & COO
    CDMOs On The Rise CDMOs On The Rise
    Catalent Invests $14M to Expand Biologics Packaging Capabilities Catalent Invests $14M to Expand Biologics Packaging Capabilities
    Catalent Expands Shanghai Clinical Packaging Capabilities Catalent Expands Shanghai Clinical Packaging Capabilities

    Related Features

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Drug Development | Drug Discovery | R&D
      R&D Outsourcing Trends

      R&D Outsourcing Trends

      Highly specialized drug products and capacity needs drive increased reliance on contract service providers.
      Kristin Brooks, Managing Editor, Contract Pharma 10.14.20

    • Drug Development | Preclinical Outsourcing
      Preclinical Planning for Successful Drug Development

      Preclinical Planning for Successful Drug Development

      When the preclinical pressure is on, appropriate planning can make sure timelines are achievable.
      Mingyi Trimble, WuXi AppTec 09.09.20


    • APIs | Drug Development | Risk Management
      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-molecule drug development has become more complex and challenging, leading to greater reliance on CDMOs.
      Sarah Bethune, Cambrex 09.09.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Drug Development | Regulatory Affairs
      Guidelines in Toxicology: A Blessing and a Curse

      Guidelines in Toxicology: A Blessing and a Curse

      A look at the evolution of drug development regulatory guides.
      Sarah Gould, Senior Principal Scientific Advisor, Charles River 09.16.19


    • Drug Development
      Flex Your Outsourcing Model to Maximize Drug Development

      Flex Your Outsourcing Model to Maximize Drug Development

      How to choose—and optimize—combinations of service models to fit your needs.
      Timothy King, Executive Director, Functional Service Partnerships (FSP), PPD 09.16.19

    • Biologics, Proteins, Vaccines | Drug Delivery | Drug Development
      Knowledge Sharing: Biologics Development and Delivery

      Knowledge Sharing: Biologics Development and Delivery

      The increasing importance of sharing information to build awareness and better manage the complexities of drug development.
      Fran L. DeGrazio, Vice President of Scientific Affairs and Technical Services, West Pharmaceutical Services 09.16.19

    • Drug Development
      Improving Your Development Program

      Improving Your Development Program

      Seven lab science trends driving the future of drug development.
      Jenifer Vija, Liam Moran, Chris Loosbroock and Eric Snyder, Charles River 05.07.19


    • Drug Development
      Technical Advantages of Continuous Flow Chemical Synthesis

      Technical Advantages of Continuous Flow Chemical Synthesis

      Continuous flow chemistry is known for its ability to handle hazardous reactions safely, but can also unlock many other technological benefits.
      Shawn Conway, Engineering R&D Director, Cambrex High Point 04.05.19

    • Drug Development
      Future Trends in the CDMO Space

      Future Trends in the CDMO Space

      And how to navigate them for successful drug development
      Guillaume Plane, Global Development and Marketing Manager, BioReliance End-to-End Solutions, MilliporeSigma 01.25.19

    • APIs | Cytotoxics and High Potency Manufacturing | Drug Development
      CDMOs On The Rise

      CDMOs On The Rise

      Tracking growth and strategies in the CDMO business
      Michel Le Bars, Managing Partner, Kurmann Partners AGe 01.25.19


    • Drug Development | Formulation Development
      Abuse Deterrent Formulations

      Abuse Deterrent Formulations

      A look at opioid abuse in North America and formulations to help avoid an epidemic.
      Damon Smith, Richard Dart and Christopher Hirst 11.13.18

    • Drug Development
      Streamlining Drug Development:

      Streamlining Drug Development:

      Four key takeaways from Veeva’s 2018 R&D Summit
      Henry Levy, General Manager of Vault CDMS, Veeva Systems 11.13.18

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Haste Makes Waste

      Haste Makes Waste

      When to sprint and when to breathe in the race from lab to clinic.
      Christian Cattaruzza, MilliporeSigma 09.11.18

    Trending
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Bormioli Opens New Glass Research Center
    • WuXi AppTec Completes OXGENE Acquisition
    • Arcline Investment Acquires ChargePoint Technology
    Breaking News
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    • Four Female Leaders Appointed to Cell & Gene CDMO
    • Fusion Pharmaceuticals Acquires IPN-1087
    • Strata Oncology Unveils Strata PATH Trial
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Gadot Biochemical Launches New Magnesium Ingredients
    Low Levels of Vitamin D and Calcium Linked to COVID-19 Severity
    Probiotic Evidenced to Assist Digestive Recovery from a Complex Surgery
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Benjamin Moore Launches COMMAND
    AOC Announces EMEA Price Increase
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Philips, Disney Join Forces to Reduce Childrens' MRI Anxiety
    Philips, Disney Partner to Improve MRI Experience for Children
    FDA OKs Asensus' Senhance for General Surgery
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Innoforce and dMed Enter Development Collaboration
    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    Four Female Leaders Appointed to Cell & Gene CDMO
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    P&G Makes Progress Toward Packaging Circularity in Europe
    Coty Partners with LanzaTech to Introduce Sustainable Ethanol
    Remembering Fred Segal, a Trendsetting Retail Pioneer
    Happi

    Latest Breaking News From Happi

    Coty Partners with LanzaTech to Reduce Its Environmental Impact
    Waterless Beauty, Simplified Routines Shape Clean Beauty at Whole Foods
    Redken Updates Packaging, Adds New Products
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Ashland announces PSA price hike in North America
    Arrow Systems and Sihl form flexible packaging partnership
    Flint Group Packaging announces global price increase
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Joa Announces Expandable Absorbent Core Wrap Solution
    Principle Business Enterprises Celebrates 60 Years
    Mann+Hummel Invests in Pamlico Air
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Spinal Elements Relaunches the Luna XD and Orbit Systems
    Coronavirus Triggers Double-Digit Revenue Dropoff at Smith+Nephew
    FDA Approves Accufix Surgical's Accu-Joint Hemi Implant
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login